Nov 06, 2023
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
Oct 30, 2023
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Oct 17, 2023
AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs
Oct 17, 2023
AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs
Sep 22, 2023
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Sep 11, 2023
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
Sep 05, 2023
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 23, 2023
AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements
Aug 15, 2023
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
Aug 09, 2023
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
 1   2   3     4    5   6   7   8   9 
 <<   <   >   >>